Pfizer Inc. (PFE) has disclosed the death of a participant in a long-term extension study of marstacimab, its hemophilia therapy that won FDA approval just last October. The news underscores the delicate balance researchers face when developing treatments that essentially recalibrate the body's clotting system.

The European Hemophilia Consortium, a non-profit organization, reported the development, which has triggered a comprehensive safety review and prompted Pfizer to take a fresh look at how surgical procedures are managed in patients taking the drug.

What Happened

The patient died on December 14, 2025, after experiencing serious adverse events including a cerebellar infarction followed by cerebral hemorrhage. The individual had hemophilia A with inhibitors and had completed the active treatment phase of the parent trial before entering the extension study.

Here's where it gets complicated: the fatal event occurred while the patient was receiving marstacimab prophylaxis and recombinant factor VIIa for perioperative bleeding management following minor surgery. That combination of therapies during a surgical procedure is precisely the kind of scenario that raises red flags about thrombotic risk.

Pfizer, working with the study investigator and an independent Data Monitoring Committee, is now conducting a detailed review to figure out what contributed to the outcome. They're looking at underlying conditions, other medications the patient was taking, and whether there's a direct link to the treatment itself. Regulatory authorities have been notified, as required, and surgical management protocols across the entire marstacimab program are being reassessed.

The Thrombotic Risk Trade-Off

Thrombotic events are, unfortunately, a known risk with rebalancing therapies like marstacimab. The drug works by inhibiting tissue factor pathway inhibitor, which increases thrombin generation. That's the whole point when you're treating hemophilia, but it's a careful balancing act.

Similar events have been reported with other non-factor hemophilia therapies, especially around surgical procedures and when combined with clotting factors or bypassing agents. It's the medical equivalent of trying to tune an instrument while someone's playing it.

Worth noting: marstacimab is approved in Europe for patients with hemophilia A or B without inhibitors. Its use in patients with inhibitors, like the patient who died, remains investigational and is still under clinical evaluation. The FDA approved Hympavzi (marstacimab-hncq) in October 2024 for routine prophylaxis to prevent or reduce bleeding episodes in adults and pediatric patients with hemophilia A (congenital factor VIII deficiency) or hemophilia B (congenital factor IX deficiency).

The Efficacy Data Looked Promising

This tragedy comes against a backdrop of otherwise encouraging clinical results. Back in June, Pfizer released topline results from the Phase 3 BASIS study evaluating marstacimab for adults and adolescents with hemophilia A or B with inhibitors.

The study met its primary endpoint and key secondary bleeding endpoints, demonstrating that once-weekly subcutaneous Hympavzi was superior to on-demand treatment in improving key bleeding outcomes. For a patient population desperately seeking less burdensome treatment approaches, this was significant news.

In December, Pfizer presented detailed results from the BASIS study showing that Hympavzi reduced bleeds by 93% compared to on-demand treatment with bypassing agents. Those are the kind of numbers that get clinicians excited, even as they remain vigilant about safety signals.

The question now is how this adverse event will affect the drug's trajectory, particularly for the investigational use in patients with inhibitors. Pfizer shares were down 0.73% at $25.02 following the news.